Skip to Content
Merck
  • Verified clinical failure with cefotaxime 1g for treatment of gonorrhoea in the Netherlands: a case report.

Verified clinical failure with cefotaxime 1g for treatment of gonorrhoea in the Netherlands: a case report.

Sexually transmitted infections (2014-08-13)
Alje P van Dam, Marc L van Ogtrop, Daniel Golparian, Jan Mehrtens, Henry J C de Vries, Magnus Unemo
ABSTRACT

We describe the first case of treatment failure of gonorrhoea with a third generation cephalosporin, cefotaxime 1g intramuscularly, in the Netherlands. The case was from a high-frequency transmitting population (men having sex with men) and was caused by the internationally spreading multidrug-resistant gonococcal NG-MAST ST1407 clone. The patient was clinically cured after treatment with ceftriaxone 500 mg intramuscularly and this is the only third generation cephalosporin that should be used for first-line empiric treatment of gonorrhoea. Increased awareness of failures with third generation cephalosporins, enhanced monitoring and appropriate verification of treatment failures including more frequent test-of-cures, and strict adherence to regularly updated treatment guidelines are essential globally.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cefotaxime sodium salt, potency: 916-964 μg per mg
Sigma-Aldrich
Cefotaxime sodium salt, suitable for plant cell culture, BioReagent, powder or crystals
USP
Cefotaxime sodium, United States Pharmacopeia (USP) Reference Standard
Cefotaxime sodium, European Pharmacopoeia (EP) Reference Standard
Cefotaxime for peak identification, European Pharmacopoeia (EP) Reference Standard
Cefotaxime acid, European Pharmacopoeia (EP) Reference Standard